AU2012340887A1 - Small molecule enhancer for dendritic cell cancer vaccines - Google Patents
Small molecule enhancer for dendritic cell cancer vaccines Download PDFInfo
- Publication number
- AU2012340887A1 AU2012340887A1 AU2012340887A AU2012340887A AU2012340887A1 AU 2012340887 A1 AU2012340887 A1 AU 2012340887A1 AU 2012340887 A AU2012340887 A AU 2012340887A AU 2012340887 A AU2012340887 A AU 2012340887A AU 2012340887 A1 AU2012340887 A1 AU 2012340887A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- compound
- mammal
- tumors
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018204591A AU2018204591A1 (en) | 2011-11-22 | 2018-06-25 | Small molecule enhancer for dendritic cell cancer vaccines |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161562497P | 2011-11-22 | 2011-11-22 | |
| US61/562,497 | 2011-11-22 | ||
| PCT/US2012/065236 WO2013078059A1 (en) | 2011-11-22 | 2012-11-15 | Small molecule enhancer for dendritic cell cancer vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018204591A Division AU2018204591A1 (en) | 2011-11-22 | 2018-06-25 | Small molecule enhancer for dendritic cell cancer vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2012340887A1 true AU2012340887A1 (en) | 2014-07-03 |
Family
ID=48470210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012340887A Abandoned AU2012340887A1 (en) | 2011-11-22 | 2012-11-15 | Small molecule enhancer for dendritic cell cancer vaccines |
| AU2018204591A Abandoned AU2018204591A1 (en) | 2011-11-22 | 2018-06-25 | Small molecule enhancer for dendritic cell cancer vaccines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018204591A Abandoned AU2018204591A1 (en) | 2011-11-22 | 2018-06-25 | Small molecule enhancer for dendritic cell cancer vaccines |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9284337B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2782994B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6240083B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN106075450A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2012340887A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2856379A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1201871A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL232664A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013078059A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9284337B2 (en) * | 2011-11-22 | 2016-03-15 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
| WO2016085943A1 (en) | 2014-11-25 | 2016-06-02 | Rastelli, Luca | Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2 |
| CA2991628C (en) * | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| US11000521B2 (en) | 2015-08-03 | 2021-05-11 | Institut Pasteur | Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy |
| WO2018049027A1 (en) * | 2016-09-07 | 2018-03-15 | Trustees Of Tufts College | Combination therapies using immuno-dash inhibitors and pge2 antagonists |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US11559537B2 (en) | 2017-04-07 | 2023-01-24 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists |
| WO2018187698A2 (en) * | 2017-04-07 | 2018-10-11 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists |
| JP2019208422A (ja) * | 2018-06-04 | 2019-12-12 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040145A (en) * | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
| CA2339537A1 (en) * | 1998-08-21 | 2000-03-02 | Barbara Wallner | Regulation of substrate activity |
| HK1046846A1 (zh) | 1999-05-25 | 2003-01-30 | Point Therapeutics, Inc. | 包含boroproline的抗肿瘤复合物 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| CN100392074C (zh) * | 2003-10-15 | 2008-06-04 | 上海海欣生物技术有限公司 | 树突状细胞肿瘤疫苗及其制法和用途 |
| CN101247799B (zh) * | 2005-07-05 | 2013-03-27 | 塔夫茨大学信托人 | 成纤维细胞活化蛋白α的抑制剂 |
| CN101379069A (zh) * | 2005-12-19 | 2009-03-04 | 塔夫茨大学信托人 | 软蛋白酶抑制剂及其前软形式 |
| WO2007123686A2 (en) * | 2006-03-31 | 2007-11-01 | Point Therapeutics, Inc. | Dpp inhibitors and uses thereof |
| CA2681351A1 (en) * | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein, and methods of use thereof |
| EP2154243B1 (en) * | 2007-05-17 | 2016-01-13 | ID Pharma Co., Ltd. | Method for production of dendritic cell |
| JP5721441B2 (ja) * | 2008-01-31 | 2015-05-20 | キュアバック ゲーエムベーハーCurevac Gmbh | 免疫賦活剤/アジュバントとしての式(I)(NuGlXmGnNv)aで表される核酸分子及びその誘導体 |
| US9284337B2 (en) * | 2011-11-22 | 2016-03-15 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
-
2012
- 2012-11-15 US US14/353,408 patent/US9284337B2/en active Active
- 2012-11-15 EP EP12850873.6A patent/EP2782994B1/en active Active
- 2012-11-15 JP JP2014543501A patent/JP6240083B2/ja active Active
- 2012-11-15 AU AU2012340887A patent/AU2012340887A1/en not_active Abandoned
- 2012-11-15 CN CN201610493117.7A patent/CN106075450A/zh active Pending
- 2012-11-15 WO PCT/US2012/065236 patent/WO2013078059A1/en not_active Ceased
- 2012-11-15 EP EP16180971.0A patent/EP3106173A1/en not_active Withdrawn
- 2012-11-15 CN CN201280067478.5A patent/CN104039952A/zh active Pending
- 2012-11-15 HK HK15102280.8A patent/HK1201871A1/xx unknown
- 2012-11-15 CA CA2856379A patent/CA2856379A1/en not_active Abandoned
-
2014
- 2014-05-18 IL IL232664A patent/IL232664A0/en unknown
-
2015
- 2015-11-23 US US14/948,777 patent/US9839646B2/en active Active
-
2017
- 2017-08-22 JP JP2017159116A patent/JP2017214420A/ja active Pending
- 2017-11-20 US US15/817,754 patent/US20180092933A1/en not_active Abandoned
-
2018
- 2018-06-25 AU AU2018204591A patent/AU2018204591A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9284337B2 (en) | 2016-03-15 |
| IL232664A0 (en) | 2014-07-31 |
| EP2782994A4 (en) | 2015-07-15 |
| CN106075450A (zh) | 2016-11-09 |
| US20160310513A1 (en) | 2016-10-27 |
| US20140271725A1 (en) | 2014-09-18 |
| AU2018204591A1 (en) | 2018-07-12 |
| HK1201871A1 (en) | 2015-09-11 |
| JP6240083B2 (ja) | 2017-11-29 |
| EP3106173A1 (en) | 2016-12-21 |
| JP2014533727A (ja) | 2014-12-15 |
| US9839646B2 (en) | 2017-12-12 |
| US20180092933A1 (en) | 2018-04-05 |
| EP2782994B1 (en) | 2017-05-10 |
| WO2013078059A1 (en) | 2013-05-30 |
| CN104039952A (zh) | 2014-09-10 |
| CA2856379A1 (en) | 2013-05-30 |
| EP2782994A1 (en) | 2014-10-01 |
| JP2017214420A (ja) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9839646B2 (en) | Small molecule enhancer for dendritic cell cancer vaccines | |
| KR20200103040A (ko) | Tlr7 아고니스트를 포함하는 병용 약물 | |
| Yao et al. | It’s high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer | |
| Yue et al. | A DXd/TLR7-agonist dual-conjugate anti-HER2 ADC exerts robust antitumor activity through tumor cell killing and immune activation | |
| WO2018053270A1 (en) | Modified natural killer cells for the treatment of cancer | |
| US12213978B2 (en) | Madrasin-derivative compounds, composition and uses thereof for treating cancer | |
| CN110891944B (zh) | 用于治疗癌症的化合物、组合物及其用途 | |
| HK1229708A (en) | Small molecule enhancer for dendritic cell cancer vaccines | |
| HK1229708A1 (en) | Small molecule enhancer for dendritic cell cancer vaccines | |
| US20220313724A1 (en) | Compositions for intratumoral administration and related methods | |
| Dyevoich et al. | Type I IFN, Ly6C+ cells, and phagocytes support suppression of peritoneal carcinomatosis elicited by a TLR and CLR agonist combination | |
| CN115282280A (zh) | TGF-β1信号抑制剂的新用途 | |
| KR20220004025A (ko) | 종양-선택적 병용 요법 | |
| CA3059270C (en) | Compounds, composition and uses thereof fortreating cancer | |
| WO2025219595A1 (en) | Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy | |
| KR20230084177A (ko) | 결핵균 추출물의 신규 용도 | |
| EP3854411A1 (en) | Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy | |
| JP2018527010A (ja) | 抗fugetactic特性を有する改変されたT細胞およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |